期刊
AGING-US
卷 13, 期 9, 页码 12395-12409出版社
IMPACT JOURNALS LLC
DOI: 10.18632/aging.202944
关键词
budding uninhibited by benzimidazoles; sarcoma; oncogene
The study found that the expression levels of BUB1, BUB1B, and BUB3 were higher in sarcoma samples and cell lines compared to normal controls. Survival analysis indicated that higher expression levels of BUB1, BUB1B, and BUB3 were associated with lower overall and disease-free survival in sarcoma patients. These findings suggest that BUB1, BUB1B, and BUB3 could be potential treatment targets and new biomarkers for prognosis in sarcoma patients.
Budding Uninhibited By Benzimidazoles are a group of genes encoding proteins that play central roles in spindle checkpoint during mitosis. Improper mitosis may lead to aneuploidy which is found in many types of tumors. As a key mediator in mitosis, the dysregulated expression of BUBs has been proven to be highly associated with various malignancies, such as leukemia, gastric cancer, breast cancer, and liver cancer. However, bioinformatic analysis has not been applied to explore the role of the BUBs in sarcomas. Herein, we investigate the transcriptional and survival data of BUBs in patients with sarcomas using Oncomine, Gene Expression Profiling Interactive Analysis, Cancer Cell Line Encyclopedia, Kaplan-Meier Plotter, LinkedOmics, and the Database for Annotation, Visualization and Integrated Discovery. We found that the expression levels of BUB1, BUB1B and BUB3 were higher in sarcoma samples and cell lines than in normal controls. Survival analysis revealed that the higher expression levels of BUB1, BUB1B and BUB3 were associated with lower overall and disease-free survival in patients with sarcomas. This study implies that BUB1, BUB1B and BUB3 are potential treatment targets for patients with sarcomas and are new biomarkers for the prognosis of sarcomas.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据